• Topic

  • Year

SUDEP: Biomarkers and Pathobiology

Sanjay Sisodiya, PhD, FRCP

University College London

Gene Therapy for the Catastrophic Type 1 Progressive Myoclonus Epilepsy (EPM1)

Berge Minassian, MD

The University of Texas Southwestern Medical Center

Harnessing the Fly Model System to Understand How Sleep Disruption Worsens Seizure Burden

Vishnu Cuddapah, MD, PhD

The Children’s Hospital of Philadelphia

Virtual Stimulation of Interictal EEG and MEG Networks to Measure Cortical Excitability in Epileptogenic Networks

Rachel June Smith, PhD

University of Alabama at Birmingham

The Joseph Gomoll Foundation

Convergence of High Frequency Oscillations with Genetic and Epigenetic Profiles in Epileptic Networks: Towards Novel Diagnostics in Focal Epilepsies

Gemma Carvill, PhD

Northwestern University

Multimodal Profiling of Neuronal Morphology, Physiology and Gene Expression in Focal Cortical Dysplasia

Cathryn Cadwell MD, PhD

University of California, San Francisco

Blood-Brain Barrier Dysregulation as a Driver of Drug-Resistant Epilepsy

Chris Greene, PhD

Trinity College Dublin

Sponsored by the Robert Withrow Wier Fund

Characterization of a Novel Dup(Atp10a-Tub5gcp5) ‘Dup15q’ Mouse Model with Varying Levels of UBE3A

Ype Elgersma

Erasmus University Medical Center (Erasmus MC)

Sponsored by the Robert Withrow Wier Fund

Reconstructing the Longitudinal Disease History in SCN8A-Related Disorders

Jillian McKee, MD, PhD

The Children's Hospital of Philadelphia

Sponsored by the Robert Withrow Wier Fund

Increasing KANSL1 Expression Through Modulation of Endogenous Anti-Sense RNAs

Hans von Bokhoven, PhD

Stichting Radboud Universitair Medisch Centrum (Radboudumc)

Robert Withrow Wier Grant

iPSC-Derived Hypoimmunogenic Human Migratory Cortical Interneurons to Treat Intractable Epilepsy

Sangmi Chung, PhD

New York Medical College

Robert Withrow Wier Grant

Preclinical Testing of Oral KCC2 Potentiator Drug AXN-006-01-3 to Rescue Phenobarbital-Resistant Neonatal Seizures

Shilpa Kadam, PhD

Axonis Therapeutics, Inc.

1 2 23